GNI Group Ltd.
2160.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$210.57B
Close$
$69.51
97.8% downside
Current Fair Value
97.8% downsideOvervalued by 97.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $210.57 Billion |
|---|---|
| Enterprise Value | $198.48 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-84.08 |
| Beta | 1.23 |
| Outstanding Shares | 55,806,520 |
Return
| Return on Equity | -13.56% |
|---|---|
| Return on Assets | -6.71% |
| Return on Invested Capital | -2.20% |
Valuation & Multiples
| P/E Ratio | -31.2 |
|---|---|
| PEG | 22.92 |
| Price to Sales | 6.74 |
| Price to Book Ratio | 2.69 |
| Enterprise Value to Revenue | 7.48 |
| Enterprise Value to EBIT | -126.19 |
| Enterprise Value to Net Income | -37 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-61.64
Average shareholder expectationRevenue Estimate
$5.44 B
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$27.30
Average shareholder expectationRevenue Estimate
$15.49 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About GNI Group Ltd.
990 employees
CEO: Ying Luo GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is...